Area of research
Oncology · Immunology
Research interest
Research interests include CAR-T cell therapy research, Immune Cell Function and Interaction, Immunotherapy and Immune Responses, and Acute Lymphoblastic Leukemia research.
Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia.
Rational redesign of antigen binding domain improves in vivo efficacy of the CD22-CAR
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies
Antigen experience history directs distinct functional states of CD8<sup>+</sup> CAR T cells during the antileukemia response.
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia.
The Paradox of Acute Myeloid Leukemia Responsiveness to Adoptive T-cell Therapy.
High Precision Peptide-MHC Class I CARs Enhance <i>In Vivo</i> Killing of Targeted CD8 T Cells to Prevent Type 1 Diabetes in Novel RIP-mOVA Model
Rational redesign of antigen binding domain improves <i>in vivo</i> efficacy of CD22-CAR T cells
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome.
Two decades of advances in clinical oncology — lessons learned and future directions
Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice
Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias
Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias.
Digital polymerase chain reaction strategies for accurate and precise detection of vector copy number in chimeric antigen receptor T-cell products.
CD4<sup>+</sup> CAR T cells - more than helpers.
Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects.
Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes
The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes.
The CD19neg needle in the haystack.
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells.
Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
Optimizing CARs for ocular delivery.
Using erythrocyte tools to enhance CAR T cells.
Mechanisms of resistance to CAR T cell therapy